Compare Amgen, Inc. (AMGN) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Ryanair Holdings plc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Ryanair Holdings plc trades at $63.89 (market cap $31.76B). The key difference: Amgen, Inc. is far larger — about 6.2× Ryanair Holdings plc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | RYAAY | |
|---|---|---|
Market Cap | $196.12B | $31.76B |
Sector | Health | Industrials |
52-Week High | $388.16 | $73.82 |
52-Week Low | $271.18 | $53.24 |
Enterprise Value | $241.41B | $29.42B |
Dividend Yield | 2.77% | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
RYAAY trades at $64.65, up 0.78% today, with a bullish technical signal and strong fundamentals including a 13.9 P/E ratio and 25.37% ROE. Recent earnings beat expectations in three of the last four quarters, and June 2026 traffic grew 7% year-over-year. The company maintains a debt-free balance sheet after repaying its final bond in May 2026, enhancing financial flexibility amid sector volatility.
Outlook remains positive with analyst consensus at 62.5% buy ratings, supported by robust operational execution and 80% fuel hedging for 2027. Key risks include rising operating costs, geopolitical tensions affecting fuel prices, and regulatory scrutiny over seating policies. The stock's valuation appears reasonable relative to earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
